KYORIN Signs License Deal with US Biotech Firm for Autoimmune Drug in Japan

MT Newswires Live

Oct 01, 2025

KYORIN Pharmaceutical (TYO:4569) said it signed an exclusive license agreement with U.S.-based biotechnology firm Hinge Bio to develop and commercialize HB2198 in Japan, according to a Wednesday filing on the Tokyo Stock Exchange.

Kyorin will pay $10 million upfront and up to $95 million in milestones tied to systemic lupus erythematosus (SLE), along with royalties on sales. The Japanese drugmaker will also share in clinical development costs.

HB2198, a bispecific antibody that targets CD19 and CD20 molecules on B cells, is designed to reset the immune system and is being prepared for a Phase 1 trial in the U.S. for SLE.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2572585893"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2572585893\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2572585893?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-01 14:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2572585893","market":"nz","top_or_hot":-1,"title":"KYORIN Signs License Deal with US Biotech Firm for Autoimmune Drug in Japan","media":"MT Newswires Live","content":"<html><body><p> KYORIN Pharmaceutical (TYO:4569) said it signed an exclusive license agreement with U.S.-based biotechnology firm Hinge Bio to develop and commercialize HB2198 in Japan, according to a Wednesday filing on the Tokyo Stock Exchange.</p><p>Kyorin will pay $10 million upfront and up to $95 million in milestones tied to systemic lupus erythematosus (SLE), along with royalties on sales. The Japanese drugmaker will also share in clinical development costs.</p><p>HB2198, a bispecific antibody that targets CD19 and CD20 molecules on B cells, is designed to reset the immune system and is being prepared for a Phase 1 trial in the U.S. for SLE.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>KYORIN Signs License Deal with US Biotech Firm for Autoimmune Drug in Japan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKYORIN Signs License Deal with US Biotech Firm for Autoimmune Drug in Japan\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-10-01 14:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> KYORIN Pharmaceutical (TYO:4569) said it signed an exclusive license agreement with U.S.-based biotechnology firm Hinge Bio to develop and commercialize HB2198 in Japan, according to a Wednesday filing on the Tokyo Stock Exchange.</p><p>Kyorin will pay $10 million upfront and up to $95 million in milestones tied to systemic lupus erythematosus (SLE), along with royalties on sales. The Japanese drugmaker will also share in clinical development costs.</p><p>HB2198, a bispecific antibody that targets CD19 and CD20 molecules on B cells, is designed to reset the immune system and is being prepared for a Phase 1 trial in the U.S. for SLE.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4077","symbol_name":"互动媒体与服务","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2572585893","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2572585893","pubTimestamp":1759299122,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"KYORIN Pharmaceutical  said it signed an exclusive license agreement with U.S.-based biotechnology firm Hinge Bio to develop and commercialize HB2198 in Japan, according to a Wednesday filing on the Tokyo Stock Exchange.Kyorin will pay $10 million upfront and up to $95 million in milestones tied to systemic lupus erythematosus , along with royalties on sales. The Japanese drugmaker will also share in clinical development costs.HB2198, a bispecific antibody that targets CD19 and CD20 molecules on B cells, is designed to reset the immune system and is being prepared for a Phase 1 trial in the U.S. for SLE.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4077":"互动媒体与服务","SLE":"Super League Gaming Inc."},"translate_title":"KYORIN与美国生物技术公司在日本签署自身免疫药物许可协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SLE":1},"content_text":"KYORIN Pharmaceutical (TYO:4569) said it signed an exclusive license agreement with U.S.-based biotechnology firm Hinge Bio to develop and commercialize HB2198 in Japan, according to a Wednesday filing on the Tokyo Stock Exchange.Kyorin will pay $10 million upfront and up to $95 million in milestones tied to systemic lupus erythematosus (SLE), along with royalties on sales. The Japanese drugmaker will also share in clinical development costs.HB2198, a bispecific antibody that targets CD19 and CD20 molecules on B cells, is designed to reset the immune system and is being prepared for a Phase 1 trial in the U.S. for SLE.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}